Posts

genomes

Scientists Create First Viruses Designed By AI, What Does This Mean For The Future Of Medicine?

Scientists have created the first viruses that were designed using artificial intelligence. This feat is being highly debated within the scientific community as both a major milestone advancement for medicine, and a potential threat if this technology isn’t protected. 

Dr. Brian Hie is a chemical engineer at Stanford University in California, who utilized genome language models to design functioning genomes for bacteriophages. The models are the genetic equivalent to the language models used for AI chatbots, and bacteriophages are the specific viruses that only infect bacteria, so they’re used to treat patients with persistent infections. 

The viruses were then made in the laboratory and specifically put against E. coli in a dish, according to the research recently published in the journal Science. “The ability to rapidly design genomes and tune them for specific bugs while overcoming resistance could transform phage therapy and expand biotechnological toolkits,” the researchers wrote. 

Embed from Getty Images

On the other hand, the scientists have also stated that the new work raised “important biosafety, biocontainment, and biosecurity consideration,” telling other people who are designing whole genomes to “consult both safety and security professionals throughout the project.”

Professor Tom Inglesby and Dr. Mori Hanke at the Center for Health Security at Johns Hopkins University wrote an accompanying article in which they emphasized the researchers safety warnings: 

“Although this is promising for life sciences applications, it also raises urgent biosafety and biosecurity questions. The ability to compose viral genomes using generative AI now exists; the governance to safely steer it does not.”

Dr. Hie and his colleagues mapped out in their article how they used AI models named Evo1 and Evo2 to design the new viral genomes. The models were specifically trained with genetic data from 2 million bacteriophages.

To keep the focus on the bacteriophages that can be utilized in medicine, the scientists made sure to carefully exclude any genetic codes for viruses that can infect living beings so the AI training doesn’t design any dangerous viruses. 

The AI worked to generate thousands of potential genomes, and the researchers chose about 300 to then make in a lab. Those genomes were then dropped into bacteria which read the genetic code and created the new bacteriophages. 

Only 16 bacteriophages were viable, however, the makeup of them were able to overcome resistance in two different strains of E. coli

Professor Inglesby and Dr. Hanke said that although only 16 out of the 300 were viable, the work proves that generative AI can create viral genomes, and there should be safeguards put into place to ensure that the technology can never be used to create pathogens that can infect plants, animals, and especially humans. 

Embed from Getty Images

“Such genomes might encode new pathogens that … cannot be contained by existing countermeasures,” they wrote

Tom Ellis, a professor of synthetic genome engineering at Imperial College London, stated that this work was very impressive, but when it comes to creating more complex genomes, there’s a lot more work to actually be done. 

“This is literally the smallest and easiest genome to make,” he said. 

“An AI trained on the genetic code of dangerous bugs could be used to design more harmful viruses,” the Guardian reported that Ellis said. 

“But controlling access to genetic data and having restrictions on making genomes that look dangerous would help. Governments are working hard to do this already,” he added.

“But honestly, the threat from full AI design and writing of a genome of a virus or bacteria is very overblown when we consider that just taking existing pathogens and making gain-of-function changes to their genomes is so much easier and much more likely to be a real pathogenic threat.”

Dr. Filippa Lentzos, a reader in science and international security at King’s College London, stated that one of the biggest things to now look out for with this type of work is making sure no scientific groups try to manufacture anything involving DNA. 

“It’s important to see the bigger governance picture and not focus regulation solely on the AI model,” she said

“A layered approach makes more sense: safeguards around model development and access, responsible research review, synthesis screening, and established laboratory biosafety and biosecurity.”

heart

‘Gamechanger’ New Findings On Treating Heart Conditions Presented In Europe 

The 2025 annual meeting at the European Society of Cardiology had doctors, scientists, and researchers presenting new findings on ways to tackle heart conditions, many of which are being considered major “gamechangers.”

virtual

Virtual Home Tours Have Taken Over The Real Estate Industry

In the real estate industry, virtual tours of prospective properties have made it easy for agents and their clients to view and discuss future transactions. Beyond the obvious health and safety benefits of this technology, virtual tours have made it easy for clients located in different states or parts of the country/world to continue their real estate dreams from the comfort of their own home.

mrna

Success Of mRNA Covid-19 Vaccines Is ‘Just A Glimpse Of Their Full Potential’

According to a new Perspective published in the Medical Journal Of Australia, the success of mRNA vaccines against Covid-19 shows “just a glimpse of their full potential.” 

Isabella Overmars is a research coordinator at the Murdoch Children’s Research Institute, and her and her colleagues are responsible for the published Perspective in which they explained why mRNA vaccines are so successful. The mRNA contains a code for a specific antigen that is transferred into a host cell where it is then translated into a coded protein. 

Embed from Getty Images

“This typically leads to the host cell displaying the protein on its surface to promote cell-mediated immunity, and the host cell releases proteins outside of the cell which are taken up and presented by other antigen-presenting cells to promote antibody-mediated immunity,” they wrote.

mRNA vaccines are being held in such high regard for a multitude of reasons, including their low toxicity, and the fact that “there is no possibility for an infection to occur from the vaccine itself”.

“mRNA vaccines do not rely on non or mildly pathogenic viral vectors as a delivery method, which in some cases can cause issues of immune-based clotting disorders, such as thrombosis with thrombocytopenia syndrome (TTS), and antivector immunity,” Overmars wrote.

“The manufacturing process also has several benefits, including in vitro development and use of synthetic materials, which improves manufacturing consistency. Moreover, mRNA vaccines can be rapidly synthesized after the required sequence is known, and modifications can be expedited, which is advantageous in responding to emerging immune-evasive variants.”

The biggest “limitation” to mRNA technology is the fact that it can be easily destroyed, which is why the vaccines need to be stored at cold temperatures.

Embed from Getty Images

“mRNA vaccine development will continue to accelerate, spurred on by the success of SARS-CoV-2 vaccines, and further improvements to the technology may mitigate some of the current limitations and facilitate broader reach.”

“For example, strategies to make the mRNA vaccines self-amplify, meaning the mRNA delivered in the vaccine encodes not only the antigen of interest but also the replication machinery that amplifies the mRNA, will reduce the amount of mRNA needed in each vaccine. Moderna is already in phase 1 with a seasonal influenza quadrivalent product, and is developing other combination vaccines, including one for human metapneumovirus and parainfluenza virus,” wrote Overmars and colleagues.

“Existing challenges need to be addressed to ensure equitable access and expansion. To do this, manufacturing facilities with advanced mRNA technology may be required in multiple locations globally,” they explained. 

“Testing of different additives, adjuvants and delivery mechanisms will be important to increase the stability of mRNA vaccines at higher temperatures and to therefore facilitate equitable access.”

“mRNA technology has progressed rapidly over the past 2 years in response to the global COVID-19 pandemic, revealing new and exciting avenues for prophylactic and therapeutic vaccine development,” they concluded.